The relative efficacy of statins in women versus men is unclear, particularly in primary prevention. To resolve this question, the Cholesterol Treatment Trialists’ Collaboration undertook a meta-analysis of data from 27 statin trials involving 174,149 people, 27% of whom were women.
As reported in The Lancet (online, 9 January 2015)
, statin therapy reduced lipid levels by a similar extent in both men and women. The incremental reduction in major vascular events with statin therapy was also similar in men and women, including in women at low baseline risk. Likewise, the proportional reductions in major coronary events, coronary revascularisation and stroke did not differ significantly by gender.
The authors conclude: “In men and women at an equivalent risk of cardiovascular disease, statin therapy is of similar effectiveness for the prevention of major vascular events.”
 Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174â000 participants in 27 randomised trials. The Lancet 2015. doi:10.1016/S0140-6736(14)61368-4.